Drug Trial News

RSS

Innovative levodopa infusion pump trial shows promise for reducing Parkinson's symptoms

An international, multisite phase 3 trial co-led by a University of Cincinnati researcher found Parkinson's disease medication delivered through an infusion pump is safe and effective at reducing symptoms for longer periods of time.

15 Mar 2024

Obesity drug tirzepatide reduces bodyweight, waist circumference regardless of the duration of disease

New research to be presented at this year's European Congress on Obesity (Venice, Italy, May 12-15) shows that the obesity medication tirzepatide consistently reduces bodyweight and waist circumference regardless of the length of time the person has been living with overweight or obesity.

13 Mar 2024

Novel CAR-T therapy shows promising results in glioblastoma patients

A collaborative project to bring the promise of cell therapy to patients with a deadly form of brain cancer has shown dramatic results among the first patients to receive the novel treatment.

13 Mar 2024

Exploristics and Exonate announce successful collaboration to enhance clinical trial study design using cloud-based simulation

Exploristics’ cloud-based simulation platform KerusCloud used to enhance study design for Exonate’s upcoming Phase IIb study following successful Phase Ib/IIa study.

12 Mar 2024

Diabetes drug dulaglutide may reduce symptoms of depression

The current study highlighted the antidepressant effects of dulaglutide using the CMS depression model. Notably, the potential metabolisms that underlie the antidepressant effect of dulaglutide have been elucidated in this study.

8 Mar 2024

Vaginal ring and oral PrEP found to be safe for HIV prevention among pregnant cisgender women

The monthly dapivirine vaginal ring and daily oral pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine were each found to be safe for HIV prevention among cisgender women who started using one of them in their second trimester of pregnancy, according to findings presented today at the 2024 Conference on Retroviruses and Opportunistic Infections (CROI) in Denver.

5 Mar 2024

Study shows semaglutide as a safe and effective therapy for MASLD in people with HIV

A weekly injection of semaglutide was safe and reduced the amount of fat in the liver by 31% in people with HIV and metabolic dysfunction-associated steatotic liver disease (MASLD), according to a presentation today at the 2024 Conference on Retroviruses and Opportunistic Infections (CROI) in Denver.

5 Mar 2024

SolasCure publishes phase IIa clinical trial report in leading wound care journal

Study demonstrates proof-of-concept and strong safety profile of Aurase Wound Gel in patients suffering from chronic wounds.

From SolasCure 4 Mar 2024

Omalizumab boosts tolerance to multiple food allergies, study finds

A study in The New England Journal of Medicine shows omalizumab increases allergen tolerance in individuals with multiple food allergies, offering a promising standalone treatment option.

26 Feb 2024

Study: Antibody combination shows safety and anti-tumor activity in advanced cancer patients

In an early phase clinical trial, a combination of antibody-based medications targeting the immune system generated promising safety data and anti-tumor activity in individuals with various types of advanced cancer.

26 Feb 2024

Off-the-shelf cancer vaccine shows promising results in patients with KRAS-mutated tumors

Samara Rahman, 74, considers herself lucky. She gets to take walks on the beach, go swimming and ride her bike -; all things that were taken from her when she was diagnosed with pancreatic cancer in November of 2022.

22 Feb 2024

Study: Early advanced therapy significantly improves Crohn's disease outcomes

A large-scale clinical trial of treatment strategies for Crohn's disease has shown that offering early advanced therapy to all patients straight after diagnosis can drastically improve outcomes, including by reducing the number of people requiring urgent abdominal surgery for treatment of their disease by ten-fold.

22 Feb 2024

Novel treatment for polycythemia vera shows promise in clinical trial

A novel treatment for polycythemia vera, a potentially fatal blood cancer, demonstrated the ability to control overproduction of red blood cells, the hallmark of this malignancy and many of its debilitating symptoms in a multi-center clinical trial led by the Icahn School of Medicine at Mount Sinai.

21 Feb 2024

Innovative treatment increases survival of people with malignant mesothelioma, trial shows

An innovative treatment significantly increases the survival of people with malignant mesothelioma, a rare but rapidly fatal type of cancer with few effective treatment options, according to results from a clinical trial led by Queen Mary University of London.

15 Feb 2024

Combination therapy shows promise in targeting latent HIV reservoirs

Antiretroviral therapies (ART) stop HIV replication in its tracks, allowing people with HIV to live relatively normal lives.

15 Feb 2024

Novel three-drug combo shows promise in advanced HER2-negative breast cancer treatment

A novel three-drug combination achieved notable responses in patients with advanced HER2-negative breast cancer, according to new research directed by investigators from the Johns Hopkins Kimmel Cancer Center.

14 Feb 2024

Combination therapy offers breakthrough in NSCLC treatment

A specific combination of targeted therapy and immunotherapy may better help patients with non-small cell lung cancer (NSCLC) overcome inherent immune resistance and reinvigorate anti-tumor activity, according to a new study led by a researcher from The University of Texas MD Anderson Cancer Center.

13 Feb 2024

Drug repurposing study finds lonafarnib effective against RSV

A study in Nature Communications identifies lonafarnib from the ReFRAME drug-repurposing library as a potent inhibitor of the RSV fusion protein, showing promise in reducing RSV infection in vitro and in vivo.

11 Feb 2024

Selective androgen receptor modulator has anti-tumor effects in ER-positive breast cancer patients

A research paper published today (8 February 2024) in The Lancet Oncology demonstrates that the drug enobosarm, a selective androgen receptor modulator which stimulates the male sex hormone receptor has anti-tumour effects in estrogen receptor positive breast cancer patients.

8 Feb 2024

AMG 133 (maridebart cafraglutide) weight loss drug shows promise in early trial

AMG 133, an engineered bispecific molecule, demonstrated significant weight loss with a favorable safety profile in a phase 1 clinical trial, offering a promising new treatment option for obesity.

7 Feb 2024